PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan
Top Cited Papers
Open Access
- 1 January 2026
- journal article
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Abstract
Chao WT, et al. J Gynecol Oncol. 2026 ;37:e75. https://doi.org/10.3802/jgo.2026.37.e75Keywords
Funding Information
- National Taiwan University Hospital Yunlin Branch (114-S012)
- Taipei Veterans General Hospital (V114C-039)
- Taipei Veterans General Hospital (V115C-095)
- Taiwan National Science and Technology Council, Executive Yuan (110-2314-B-075-016 MY3)
- Taiwan National Science and Technology Council, Executive Yuan (113-2314-B-075-057 MY3)
- Taiwan Female Cancer Foundation (JGO-25-0259)
This publication has 38 references indexed in Scilit:
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialAnnals of Oncology, 2024
- Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysisTaiwanese Journal of Obstetrics and Gynecology, 2024
- Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancerESMO Open, 2024
- Rates of genetic consultation in high‐grade serous ovarian cancer patients in the era of PARP inhibitor therapy: A population‐based studyInternational Journal of Gynecology & Obstetrics, 2024
- Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialAnnals of Oncology, 2023
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian CancerJAMA Oncology, 2023
- PARP Inhibitors in Ovarian Cancer: A ReviewTargeted Oncology, 2023
- Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialAnnals of Oncology, 2022
- A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceAnnals of Oncology, 2021
- Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancerTaiwanese Journal of Obstetrics and Gynecology, 2017